Ace the 2026 RAPS RAC-Drugs Exam – Dive into Your Regulatory Road to Success!

Biosimilars are a category of biologic products that are similar to an already approved reference product. The term that does not appropriately describe biosimilars is "monoclonal antibody." While many biosimilars can be monoclonal antibodies, the term itself refers specifically to a certain class of biologics produced from a single clone of cells and does not encompass the broader category of biosimilars.

The other terms—follow-on protein products, subsequent entry biologics, and similar biological products—are all synonymous with biosimilars. They describe products that are developed to be highly similar to an existing biologic, with no clinically meaningful differences in terms of safety, purity, or potency. Each of these terms emphasizes the regulatory framework and market context in which biosimilars operate, illustrating their role as alternatives to original biologics after the original product's patent expires.